Generic Name and Formulations:
Estradiol (as hemihydrate) 10mcg; vaginal inserts.
Indications for VAGIFEM:
Atrophic vaginitis due to menopause.
Use lowest effective dose for the shortest duration. 1 insert intravaginally once daily for 2 weeks, then 1 insert twice weekly. Reevaluate periodically.
Undiagnosed abnormal genital bleeding. Known, suspected, or history of breast cancer. Known or suspected estrogen-dependent neoplasia. Active DVT, PE, or history of these conditions. Active arterial thromboembolic disease (eg, stroke, MI) or a history of these conditions. Known protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders. Known liver impairment or disease. Known angioedema. Known or suspected pregnancy.
Endometrial cancer. Cardiovascular disorders. Breast cancer. Probable dementia.
Increased risk of cardiovascular disorders (eg, stroke, DVT). Endometrial, breast, or ovarian cancer. Risk of probable dementia in women >65yrs of age. Gallbladder disease. Bone disease associated with hypercalcemia. Visual abnormalities. Consider the addition of a progestin in patients with an intact uterus to avoid endometrial hyperplasia. History of hypertriglyceridemia. Hepatic impairment. Monitor thyroid function. Conditions aggravated by fluid retention. Hypoparathyroidism. Endometriosis. Hereditary angioedema. Caution in asthma, diabetes, epilepsy, migraines, porphyria, SLE, hepatic hemangiomas. Do initial complete physical and repeat yearly (include Pap smear, mammogram, BP). Discontinue if jaundice, cardiac events, severe hypercalcemia or pancreatitis occurs. Discontinue at least 4–6 weeks before surgery type associated with increased risk of thromboembolism or during prolonged immobilization. Nursing mothers.
May be antagonized by CYP3A4 inducers (eg, St. John's Wort, phenobarbital, carbamazepine, rifampin). May be potentiated by CYP3A4 inhibitors (eg, erythromycin, clarithromycin, ketoconazole, itraconazole, ritonavir, grapefruit juice).
See full labeling. Upper respiratory tract infection, headache, abdominal pain, back pain, genital pruritus, moniliasis, vulvovaginal mycotic infection, diarrhea; increased risk of gallbladder disease, thromboembolic disorders.
Vaginal inserts—8, 18 (w. applicators)
Clinical Pain Advisor Articles
- Opioid Use Disorders: Advances in Pharmacotherapy Provide Long-term Results
- Abuse-Deterrent Opioid Formulations: Barriers to Broader Use
- Women Frequently Prescribed High Doses of Opioids After Vaginal Delivery
- Notifications by PDMPs May Not Effectively Reduce Opioid Misuse
- Medical Cannabis Legalization Associated With Reduced Schedule III Opioid Prescriptions
- Neuropathic Pain Medications
- Higher Buprenorphine Dose May Not Increase Severity of Neonatal Abstinence Syndrome
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Ketamine Infusions May Be Effective for Refractory Headache
- Physical, Psychosocial Activity May Be Protective Against Development of Chronic Pain in Older Adults
- A Physician's Guide to Incorporating Patient Spirituality in Practice
- FDA Taps Social Media to Identify and Assess Emerging Drug Abuse Threats
- Buffered Lidocaine May Be Superior to Nonbuffered Lidocaine for Inferior Alveolar Nerve Block
- Virtual Reality May Effectively Reduce Sensory, Affective, and Cognitive Pain During Labor
- Marijuana's Uncertain Status: Closing the Gap Between State and Federal Policies